Tags : Evaluating

Clinical Trials

Dicerna Presents New Interim Data of PHYOX 3 OLE Study

Shots: The PHYOX 3 OLE study involves assessing of nedosiran in participants aged ≥6yrs. with PH1 or PH2 who have participated in any previous PHYOX clinical development program trial as well as their siblings aged 6-18yrs. with PH All participants regardless of PH subtype, achieved normal or near-normal Uox excretion @day180, 92% participants (100% & […]Read More

Biotech COVID-19

Zydus Initiates Adaptive P-I/II Clinical Study Evaluating its ZyCoV-D Against

Shots: Zydus has commenced the adaptive P-I/II human clinical trials of its plasmid DNA vaccine, ZyCoV-D and reported its first human dosing The Adaptive P-I/II dose escalation study will assess the safety, tolerability, and immunogenicity of the vaccine in ~1000 candidates across multiple clinical sites in India. The company has already manufacture clinical GMP batches […]Read More

Biotech COVID-19

Bharat Biotech to Initiate Clinical Trials Evaluating Covaxin (India’s First

Shots: Bharat Biotech has received DCGI approval to conduct P-I & II clinical studies assessing Covaxin, developed in collaboration with ICMR and NIV. The company anticipate initiating the clinical studies in July’2020 The DCGI’s approval is based on preclinical data demonstrating safety and immune response. The SARS-CoV-2 strain was isolated in NIV & transferred to […]Read More